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Edited by Sandro SonninoAbstract In this study, the eﬀects of short-term diabetes (4
days) on rat renal glomerular cells proliferation and the potential
involvement of sphingolipids in this process were investigated.
Immunohistochemical analysis showed that streptozotocin
(STZ)-induced diabetes promoted increased intra-glomerular
hyperplasia, particularly marked for mesangial cells. This was
associated with a concomitant increase in neutral ceramidase
and sphingosine-kinase activities and the accumulation of the
pro-proliferative sphingolipid sphingosine-1-phosphate, in glome-
ruli isolated from kidney cortex of STZ-treated rats. These re-
sults suggest a possible involvement of sphingolipid metabolites
in the glomerular proliferative response during the early stages
of diabetic nephropathy.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Diabetic nephropathy (DN) is one of the most frequent
causes of renal dysfunction. One of the dominant histological
features of the abnormal kidney from diabetics is the expan-
sion of the mesangium, and particularly oversecretion and
deposition of extracellular matrix (ECM) proteins (such as col-
lagen IV, ﬁbronectin and laminin B1) [1]. In addition, an
imbalance in the control of mesangial cells (MC) proliferation
appears to play an early and crucial role in the initiation and
progression of glomerulosclerosis.
It has been described in animal models or in in vitro exper-
iments that, after a short period of exposure to the diabetic
milieu, MC undergo an initial and transient proliferative stage
followed by cell cycle arrest in the G0/G1 phase, hypertrophy
and oversecretion of ECM proteins. Streptozotocin (STZ)-in-Abbreviations: CDase, ceramidase; Cer, ceramide; DN, diabetic
nephropathy; NBD-C12-Cer, (N-[12-[(7-nitro-2-1,3-benzoxadiazol-4-
yl)amino]dodecanoyl]-D-erythro-sphingosine); ECM, extracellular
matrix; MC, mesangial cells; OPA, o-phthalaldehyde; PBS, phos-
phate-buﬀered saline; S1P, sphingosine-1-phosphate; Sph, sphingo-
sine; SphK, sphingosine kinase; STZ, streptozotocin
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phagia, hyperglycemia, and hypoinsulinemia [2], promptly
develop renal enlargement and progressive clearance dysfunc-
tion, characteristic of nephropathy establishment. In this
model, hyperplasic MC in kidneys from diabetics have been
described as soon as 4–5 days after STZ injection [3].
On the other hand, the sphingolipid ceramide (Cer) is
known to play important biological function such as induc-
tion of apoptosis. In addition, Cer is a key intermediate in
the formation of biologically important sphingolipids, among
which, sphingosine (Sph) and sphingosine-1-phosphate (S1P).
In contrast to the growth inhibitory and pro-apoptotic eﬀects
of Cer and Sph [4], S1P accumulation has been shown to play
opposing roles by promoting cell growth in various cell types
including MC [5–7]. Therefore, the relative levels of these
sphingolipid metabolites have been pointed out as a sensitive
rheostat controlling growth and death of various cell types
[8,9]. Ceramidases (CDases) hydrolyze the Cer N-acyl linkage
between the fatty acyl and the Sph base, which results in the
prevailing source of cellular Sph [10]. Sph can be in turn
phosphorylated by sphingosine kinase (SphK) to form S1P.
In this way, CDase activity may be a key step in determining
the intracellular levels of Cer and Sph/S1P, thus playing a
crucial role in the regulation of cell survival or death in re-
sponse to external stimuli [11]. A previous study from our
laboratory [7] showed that CDase modulation is implicated
in the bimodal eﬀects of advanced glycation end-products
(AGE) on MC proliferation. Results showed that prolifera-
tion induced by low AGE concentrations (<1 lM) was paral-
leled by CDase and SphK activation and increased S1P
production. On the contrary, high AGE concentrations
(10 lM) inhibited MC growth through CDase and SphK
inhibition, Sph accumulation, and Cer conversion to other
antiproliferative glycosphingolipids.
These in vitro results, particularly the eﬀects of AGE at
low concentrations, prompted us to investigate the potential
implication of sphingolipid metabolism in DN using experi-
mental animal models at early stages, where AGE concentra-
tions are assumed to be low. Thus, the modiﬁcation of
sphingolipid metabolism in diabetic renal glomeruli was
investigated ex vivo. Results showed increased cellular prolif-
eration in 4-days diabetic glomeruli as compared to controls.
This was accompanied by a drastic increase of glomerular
S1P levels, which was associated to increased activity of the
S1P-generating enzymes, CDase and SphK. These results sug-
gest a possible involvement of sphingolipids in the early pro-
liferative responses during the early steps of the development
of DN.blished by Elsevier B.V. All rights reserved.
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2.1. Materials
Streptozotocin and sodium citrate were from Sigma–Aldrich (Saint
Quentin Fallavier, France). Lipids (C18- and C17-D-erythro-sphingo-
sine and S1P and C12-NBD-Cer) were purchased from Avanti Polar
Lipids (Coger, Paris, France). Bicinchoninic acid (BCA) protein assay
kit was from Pierce (Perbio Science, Bezons, France).
All solvents, glass precoated striped thin-layer chromatography
(TLC) plates (20 · 20 cm, silica gel 60), and Licrospher 100 RP-18
column (Hibar pre-packed column, RT 250-4) were from Merck
KGaA (Darmstadt, Germany). HPLC analysis was performed on an
1100 Modular 3D LC System (Agilent Technologies, Massy, France).
Autoradiography and ﬂuorescence acquisition were performed using
Storm Imaging Systems, ImageMaster VDS-CL, and ImageQuant
software for data quantitative analysis (Amersham Biosciences, Orsay,
France). Histological studies were performed on a Zeiss-Axiovert 200
microscope equipped with a mercury short-arc ﬂuorescence lamp and a
digital monochrome camera (Axiocam MRm), data being computed
with Axiovision 4.2 software (Carl Zeiss, Le Pecq, France).2.2. Animals–induction of diabetes in rats
Young Wistar male rats, weighing 176/200 g, were purchased from
Charles River (LArbresles, France). After a week resting period, over-
night fasted rats were randomly divided into two groups, each being
administered a single intravenous injection of either 65 mg/kg freshly
dissolved STZ, or an equivalent volume (160 ll) of the drug vehicle
(citrate buﬀer, pH 4.5) for control animals. During all the experiment,
animals were housed in cages with standard show and water ad libitum.2.3. Kidney samples and glomeruli isolation
STZ and control group were each composed of 6 animals, and the
experiment was carried out twice. Four days after injection, overnight
fasted STZ-treated and control rats were anaesthetised and sacriﬁced.
Body weight was checked, blood glucose levels were measured using
the glucose-oxydase colorimetric assay, and kidneys were removed.
The right kidney of each rat received a slight longitudinal incision
and was immediately post-ﬁxed in 4% paraformaldehyde baths for
24 h at room temperature. In parallel, glomeruli were obtained from
freshly isolated renal cortex fragments of the left kidney, which were
mechanically sieved and harvested by iterative selection on speciﬁc
mesh sizes (Cellector, 230-, 70- and ﬁnal 73.7-lm). Glomeruli were
then dry frozen at 70 C until further analysis.
2.4. Measurement of biochemical parameters - enzyme assays
Ceramidase assay. The assay was adapted from El Bawab et al. [12].
Glomeruli were resuspended in lysis buﬀer (25 mM HEPES, pH 7.5,
5 mM EDTA, 0.2% Triton X-100, 1.5 mM sodium ﬂuoride, 1 mM so-
dium vanadate, 10 ll/ml proteases inhibitors cocktail (Protease Ar-
rest, Calbiochem, VWR International S.A.S, Fontenay-sous-Bois,
France) and homogenized by serial passes through a 23-gauge needle
ﬁtted on a 1 ml syringe. After centrifugation at 10000 · g for 5 min,
the supernatant was used for protein determination using the BCA
assay. Synthetic ﬂuorescent substrate speciﬁc for CDases (N-[12-[(7-ni-
tro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-D-erythro-sphingo-
sine) (NBD-C12-Cer) was solubilized by sonication (250 lM in 0.1%
Triton X-100). Each sample (50 lg proteins) was assayed for N-CDase
activity by incubation with 25 lM NBD-C12-Cer in 0.2 M Hepes (pH
7.5) for 2 h at 37 C. At the end of incubation, lipids including the
released NBD-dodecanoic acid were extracted with chloroform/metha-
nol (1:1, v:v), spotted onto a TLC plate together with a NBD-dodeca-
noic acid standard (10–250 pmol) and developed in chloroform/
methanol/ammonia (25:5:0.3, v:v:v). NBD-dodecanoic acid was visual-
ized and quantiﬁed by ﬂuorescent imaging. CDase speciﬁc activity was
expressed in picomoles of released fatty acid/min/mg protein.
Sphingosine kinase assay. Sphingosine kinase activity was measured
as described by Olivera et al. [13] with slight modiﬁcations as reported
[7]. Brieﬂy, glomeruli pellets were homogenized in 300 ll of lysis/reac-
tion buﬀer (20 mM Tris–pH 7.4, 20% glycerol, 1 mM b-mercap-
toethanol, 1 mM EDTA, 1 mM sodium vanadate, 15 mM sodium
ﬂuoride, 40 mM glycerophophate, 1 mM phenylmethylsulfonyl ﬂuo-
ride, 0.5 mM 4-deoxypyridoxine, 10 ll/ml protease inhibitors cocktail).
The 10000 · g supernatant was collected and used for SphK assay.SphK activity was measured in the presence of 50 lM Sph, [33P] c-
ATP (10 lCi, 1 mM) and MgCl2 (10 mM), for 1 h at 37 C. Reactions
were terminated by acidic phase separation. After TLC development,
the radioactive spots corresponding to [33P] S1P were visualized by
autoradiography, quantiﬁed and SphK speciﬁc activity was expressed
in A.U./min/mg protein.
HPLC assay of S1P and Sph. HPLC assay was used to quantitate
the released S1P and Sph, as described by Min et al. [14] and applied
in our laboratory [7]. Glomeruli pellets were resuspended in 100 ll
phosphate-buﬀered saline (PBS) and an aliquot was kept for protein
determination. Endogenous S1P was collected in aqueous phase result-
ing from iterative alkaline solvent extraction in the presence of 20 pmol
C17-sphingosine-1-P as an internal standard. Aqueous phases were
combined, mixed thoroughly with 130 ll reaction buﬀer (200 mM
Tris–HCl, pH 7.4, 75 mM MgCl2, and 2 M glycine, pH 9), 50 units
of alkaline phosphatase, and incubated for 1 h at 37 C on a 200 ll
chloroform layer placed at the bottom of the reaction mixture.
Dephosphorylated sphingoid bases were extracted twice with chloro-
form, dried under N2, dissolved in ethanol and ﬁnally derivatized with
freshly prepared o-phthalaldehyde reagent (OPA). HPLC was con-
ducted using a Hewlett–Packard 1100-HPLC model ﬁtted with a
5 lm RP-C18 column (25 · 4) combined with a guard column car-
tridge. The solvent was acetonitrile/water (90:10, v:v) and elution
was achieved for 50 min with a ﬂow rate of 1 ml/min. A spectroﬂuor-
emeter detector was used with an excitation at 340 nm and emission at
455 nm. The retention times of C17-Sph- and Sph-[OPA] were around 9
and 12 min, respectively. Chromatographic proﬁles were then analysed
using the HP Chemstation software.
For Sph measurement, standard C17-Sph was added in the residual
organic phase after primary solvent extraction. Sph derivatization and
analysis was then performed as described for S1P, excluding the preli-
minary dephosphorylation reaction.2.5. Immunohistochemical detection of proliferating cells
10 lm-thin longitudinal tissue sections coated on glass slides were
obtained from paraﬃn-embedded kidneys of control and diabetic rats.
Kidney sections were dewaxed and rehydrated in successive baths of
xylene (2 · 10 min), ethanol 100% (2 · 10 min) and PBS (5 min). The
sections were blocked in PBS 5 % horse serum, 1% BSA for 1 h, and
then incubated with mouse monoclonal primary antibodies (BD, Le
Pont-De-Claix, France) to PCNA (Proliferating Cell Nuclear Antigen)
or phycoerythrine-coupled PCNA, and Thy-1/CD-90 (a speciﬁc mar-
ker for MC), at respective 1:500 and 1:40 dilutions, overnight at
4 C. The next day, slides were gently washed for 30 min in PBS,
and incubated with a ﬂuorescein-conjugated IgG (1:50) (Sigma) for
30 min for Thy-1 detection. Controls were performed using primary
antibody (PCNA or Thy-1) exclusion and rabbit non-immune serum.
Slides were then brieﬂy washed in PBS, left to dry and mounted under
a cover-slide with a few drops of Molecular Probes Antifade (Invitro-
gen, Cergy Pontoise, France) before ﬂuorescence illumination through
appropriate ﬁlters and microscope observations. Fluorescence spots of
10 arbitrary ﬁelds per slide (one for each animal) were counted manu-
ally under a constant 40· magniﬁcation.2.6. Statistical analysis
Results are expressed as means ± S.D. Comparisons were done using
SPSS for Windows version 11.0 (SPSS, Paris, France) software. The
signiﬁcance of the diﬀerences between the two groups was analysed
by the unpaired Students t test. Probability values of less than 0.05
were considered signiﬁcant.3. Results
3.1. Short-term diabetes induces cellular proliferation in renal
glomeruli
Although early glomerular modiﬁcations appear in the
course of diabetes, few studies have addressed the biochemical
events involved in the initial proliferative induction in the glo-
merulus. Therefore, we performed experiments early (4 days)
after the induction of diabetes in the STZ-rat model, and inves-
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glomeruli from diabetic rats.
As expected, the fasting plasma levels of glucose in the STZ-
treated groups was higher than in the control group
(6.38 ± 0.81 vs. 3.2 ± 0.63 mM), and the body weight of the
STZ-induced diabetic group was slightly reduced compared
to controls (161.35 ± 5.06 vs. 187.73 ± 4.94 g).
Next, thin, longitudinal paraﬃn-embedded sections (10 lm)
of normal and diabetic rats were analysed by immunohisto-
chemistry. Our analysis focused on the glomerular area, easily
distinguished by their characteristic circular morphological as-
pect bordered by peripheral lumen. Labelling with mouse
monoclonal anti-PCNA antibody (Fig. 1A and D) showed sig-
niﬁcant increase (30%) of proliferating cell number on sections
from diabetic animals as compared to controls (Fig. 1G). An
apparent co-localisation (Fig. 1C and F) with the Thy-1 mes-
angial speciﬁc antigen (Fig. 1B and E) was most frequently ob-
served in kidneys of diabetic animals (Fig. 1H), suggesting that
MC in particular are involved in this glomerular hyper-prolif-
erative status. These results are in agreement with previous re-
port of Young et al. [3] describing a very early onset ofFig. 1. Short-term diabetes induces cell proliferation in renal glomeruli. Di
diabetic (STZ- A, B, C) or control (citrate- D, E, F) animals were harvested f
cells were distinct detected by immunohistochemistry analysis as described un
MC, respectively. Merge image is presented in (C) and (F). Pictures show insta
are representative of sections analysis of six slides per condition. (G) and (H)s
glomerulus, respectively, and represent means ± S.D. (\, P < 0.05 STZ vs. Cglomerular hypercellularity, particularly for MC within the
ﬁrst week of diabetes induction, with a peak of proliferation
at 4–5 days.
3.2. Short-term diabetes induces S1P accumulation in renal
glomeruli
Sphingolipids and in particular Cer and S1P have been
shown to play important roles in the regulation of cell growth
and cell death. Further, whereas Cer is known to exert anti-pro-
liferative and pro-apoptotic role, S1P has been shown to be
associated with cellular proliferative responses. Thus, consider-
ing the conﬁrmed eﬀects of short-term diabetes on proliferation
of glomerular cells, we examined the hypothesis that short-term
diabetes could promote S1P production able to drive glomeru-
lar proliferation. As shown in Fig. 2, in control glomeruli, low
amounts of S1P were detected. On the contrary, 4 days-diabetic
glomeruli exhibited dramatically higher amounts of S1P, with a
nearly 14-fold increase as compared to control animals (Fig.
2B). Sphingosine is a precursor of S1P, therefore, Sph levels
were measured next. As shown in Fig. 2C, Sph levels were
not aﬀected in response to STZ-induced diabetes. This lack ofabetes was induced by STZ injection in rats. After 4 days, kidneys of
or paraﬃn inclusion. PCNA+ (A and D) and Thy-1/CD-90+ (B and E)
der Section 2, for identiﬁcation and counting of proliferating cells and
nt captures with identical 40·magniﬁcation of a single glomerulus and
hows quantiﬁcations of PCNA+ and PCNA+/Thy-1+ cells identiﬁed per
ontrol).
Fig. 2. Short-term diabetes increases S1P, but not Sph levels in isolated renal glomeruli. Diabetes was induced by STZ injection in rats. After 4 days,
kidneys of diabetic (STZ) or control (citrate) animals were harvested for glomeruli isolation. S1P and Sph were measured on glomerular crude
homogenates by HPLC analysis after diﬀerential extraction and OPA-derivatization as described under Section 2. (A) represents the HPLC
chromatograms of S1P extracted from control and STZ-glomeruli. In (B), S1P levels are expressed as nmol/mg protein and represent means ± S.D. of
11–12 animals (\\\, P < 0.005 STZ vs. Control). In (C), Sph levels are expressed as nmol/mg protein and represent means ± S.D. of 11–12 animals.
1252 K. Geoﬀroy et al. / FEBS Letters 579 (2005) 1249–1254diﬀerence could be explained by the observed 10-fold higher
Sph levels than S1P ones in glomeruli (Fig. 2). These results
show a concomitant increase of S1P levels and cell proliferation
in glomeruli of diabetic kidney. They also suggest a role of S1P
in early cell proliferation of STZ-glomeruli.
3.3. Short-term diabetes induces N-CDase and SphK activities in
renal glomeruli
Current knowledge suggests that CDase and SphK are key
enzymes involved in the production of S1P in response to
various stimuli. Therefore, in the following experiments
CDase and SphK activities were measured in glomeruli ofcontrol and 4 days-STZ animals. As previously reported in
vitro [7], results showed that N-CDase activity was increased
in the 4 days-diabetic glomeruli as compared to controls (Fig.
3). The eﬀect of diabetes on CDase activity is likely caused by
higher N-CDase protein expression [7]. Next, SphK activity
was measured. Fig. 3 shows a 2.3-fold increase of SphK in
glomeruli isolated from 4 days-STZ animals. These results
suggest that the observed increase of S1P levels is caused,
at least partly, by the concomitant activation of CDase and
SphK in the STZ-glomeruli. They also support a rapid con-
version of Sph into S1P and the consequent lack of Sph
increase.
Fig. 3. Short-term diabetes induces neutral CDase and SphK activities
in isolated renal glomeruli. Homogenates of renal glomeruli were
prepared from diabetic and control rats. 100 lg proteins of total
glomerular homogenates were then used to measure N-CDase and
SphK activities as described in Section 2. In glomerular homogenates
of control rats, N-CDase speciﬁc activity was 6.47 ± 0.38 pmol/min/
mg, and SphK speciﬁc activity was 131919.7 ± 60862.5 A.U./min/mg
prot. Data are expressed as percentage of control (citrate groups) and
represent means S.D. of 10–11 animals (\, P < 0.05 STZ vs. Control).
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Mesangial cells proliferation plays a pivotal role in the path-
ogenesis of glomerular inﬂammation and ﬁbrosis leading to re-
nal diseases including DN. Hyperplasia of interstitial MC
precedes or accompanies progressive glomerular scarring, as
observed in chronic glomerulonephritis and diabetic glomeru-
losclerosis. In diabetic animal models, an increase of MC pro-
liferation has been shown to occur very early in the kidney
[15,3]. This initial and transient proliferation is followed by
mesangial cell–cell cycle arrest, hypertrophy, and overdeposi-
tion of ECM proteins into the glomerular basement membrane
leading thus to impaired glomerular ﬁltration and developing
renal failure [16]. Results from the present study conﬁrmed
that short-term 4 days diabetes induces an early increase of
glomerular cells proliferation. Thus, results obtained by immu-
nohistochemistry on kidney sections showed a signiﬁcant in-
crease of proliferating PCNA-expressing cells, preferentially
identiﬁed in glomeruli (Fig. 1) and colocalized with MC mar-
ker Thy-1.
Over the last decade, cell growth, survival, and death pro-
cesses have been associated with regulation of sphingolipid
metabolism. Cer, and two of its main metabolites, Sph and
S1P, are now recognized as essential messengers aﬀecting a
wide variety of biological activities, among which cellular pro-
liferation [17]. Although resting cells are exposed only to low
levels of these bioactive metabolites, their activation by diﬀer-
ent agonists (growth factors, cytokines) and stress agents (UV,
anticancer drugs) initiate regulation of sphingolipid metabo-
lites levels.
Original results from this study show for the ﬁrst time a
modulation of sphingolipid metabolism in 4-days diabetic
glomeruli. These eﬀects consisted in the simultaneous activa-
tion of CDase and SphK leading to S1P accumulation in dia-
betic glomeruli. The CDase–SphK pathway is now assumed as
a major pathway for cell S1P accumulation. Both enzymes arestrongly expressed in kidney [18], and have been shown in var-
ious cell types to be concomitantly activated in response to
PDGF, IL-1b, oxidized low-density lipoproteins. A previous
study from our laboratory showed that treatment of primary
cultures of MC with advanced glycation end-products (AGE)
at low concentrations (<1 lM) induced CDase–SphK activa-
tion and S1P accumulation, that was clearly associated with in-
creased cell proliferation [7]. Amadori-modiﬁed proteins as
well as AGE resulting from high glucose environment accumu-
late in vivo along various pathophysiological circumstances,
including chronic inﬂammation, senescence, and diabetes.
AGE have also been pointed out as one of the main inducers
of intrarenal growth factors, whose pivotal role in the develop-
ment of DN is now established [19]. Thus, it is tempting to
speculate that in the diabetic kidney, AGE formation or
AGE-induced growth factors could interfere with glomerular
hyperplasic modiﬁcations through modiﬁcation of sphingo-
lipid metabolism. It should be noted however, that results from
the present study could not exclude that inhibition of S1P
phosphatase and/or S1P lyase might be another additional
pathway that contributes to the observed S1P accumulation
in glomeruli.
On the other hand, inﬂammation and inﬂammatory cyto-
kines have been postulated to be important additional patho-
genetic factors in the development of diabetes [20,21]. In
vivo ﬁndings in rats with experimental glomerular disease have
supported this concept by demonstrating abnormal MC
expression of cytokines, their receptors and ECM proteins,
promoting the recruitment and activation of inﬂammatory
cells, and perpetuating MC proliferation as well as ECM
enlargement [22]. For example, intrarenal aggregation of circu-
lating platelets has been described during glomerular impair-
ment. For instance, in the STZ rat model, platelet inﬁltration
into kidneys has been described to occur only 3 days after dia-
betes induction [3]. Platelets not only exhibit active membra-
nous SphK, but also represent an important reservoir of
S1P, implicated in their paracrine stimulating properties [23].
Thus, it should be also considered that the robust increase of
S1P levels in STZ-glomeruli involves other mechanisms, such
as inﬁltrating platelets. Whatever the origin, S1P accumulation
could promote glomerular proliferation and thereby partici-
pate in the early diabetic eﬀects on nephropathy establishment.
Altogether, these observations raise the hypothesis that glo-
merular proliferation in vivo in the STZ-model might be regu-
lated by diabetic environment via modulation of sphingolipid
metabolism.
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